Where does Glaxo Group Limited rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Glaxo Group Limited ranks #2,929 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Glaxo Group Limited hold?

Glaxo Group Limited holds 130 US utility patents granted between 2015 and 2025, spanning 25 technology areas.

What is Glaxo Group Limited's Innovation Score?

Glaxo Group Limited has an Innovation Score of 43.6 out of 100 (top 28% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Glaxo Group Limited focus on?

Glaxo Group Limited's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 90 patents, ranking #174 of 6,058 assignees active in that subclass. Grants appear in 25 CPC subclasses total.

Is Glaxo Group Limited's patent grant rate increasing or decreasing?

Glaxo Group Limited's recent grant velocity is -89% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Glaxo Group Limited's patents?

Glaxo Group Limited's patents average 13.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Glaxo Group Limited patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Glaxo Group Limited

USPTO PatentsView assignee record - 130 granted patents across 25 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Glaxo ranks #2,929 of 49,997 tracked US assignees by granted-patent volume, with 130 patents across 25 technology areas.

#2,929
of 49,997 US assignees by volume: Top 28%
by Innovation Score (43.6/100): 13.8
avg claims per patent: -89%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R2929 · Foreign Corporation #2,929 · 130 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-MID 130 grants
TOP-DECILE #2,929/49,997
PHOTO-FINISH Alcon Research
CPC-FOCUS A61P · 25 areas
INNOV-PAR 43.6/100
CLAIMS-RICH 13.8 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -89% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Alcon Research, Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Glaxo’s 43.6 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 16.8 pts (39%) Velocity 0.7 pts (2%) Breadth 17.7 pts (41%) Claim depth 8.3 pts (19%)

Qualcomm Incorporated · highest

85
Cipla · near

44
Coilcraft Incorporated · near

44
Eternal Materials · near

44
Glaxo Group · this assignee

44
Inventure Labs · near

44
3D Lighting… · lowest

7

What this shows Glaxo's Innovation Score is 43.6/100 (top 28% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Glaxo?

Each dot is one of Glaxo’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Glaxo’s own 13.8 claims/patent is ABOVE the 13.4 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Glaxo vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Glaxo's grants concentrate

Glaxo Group Limited is a focused PatentsView assignee: 25 CPC subclasses with 69.2% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2015 (44 grants) versus a trough of 1 in 2022. By volume, Glaxo sits between Alcon Research, Ltd. and MTU Friedrichshafen GMBH.

Glaxo's three-year grant acceleration

Glaxo Group Limited shows 2 grants in 2022–2024 against only 18 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Alcon Research

130
Butterfly Network

130
Crown Packaging T…

130
Dalian Institute…

130
Husky Injection M…

130
Kansas State Univ…

130
Katalyst Surgical

130
MTU Friedrichshaf…

130
Glaxo Group ◀

130

What this shows Glaxo holds 130 patents at rank #2,929, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Glaxo

By rank, the assignees closest to #2,929 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Glaxo's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Glaxo, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Glaxo ranks #174 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (44 here).

Cipla Limited 44 Eternal Materials Co., Ltd. 44 Inventure Labs LLC 44 Coilcraft, Incorporated 44

Similar claim depth

Nearest assignees by average claims per patent (13.8 here).

Clark Equipment Company 13.8 avg Eppendorf AG 13.8 avg Haldor TOPSØE A/S 13.8 avg Kuraray Noritake Dental Inc. 13.8 avg

Glaxo's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

44 Top 28% higher than 72% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Glaxo Group Limited patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	44	33.8%
2016	40	30.8%
2017	20	15.4%
2018	5	3.8%
2019	7	5.4%
2020	7	5.4%
2021	4	3.1%
2022	1	0.8%
2023	1	0.8%
2025partial year	1	0.8%

Which technologies does Glaxo Group Limited patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 90

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 69

C07D - Heterocyclic Compounds 47

C07K - Peptides 29

A61Q - Specific USE OF Cosmetics OR Similar Toiletry Preparations 10

Y02A - Technologies FOR Adaptation TO Climate Change 9

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 9

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 7

C07C - Acyclic OR Carbocyclic Compounds 6

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 6

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 6

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 6

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 5

B65D - Containers FOR Storage OR Transport OF Articles OR Materials, e.g. Bags, Barrels, Bottles, Boxes, Cans, Cartons, Crates, Drums, Jars, Tanks, Hoppers, Forwarding CONTAINERS; Accessories, Closures, OR Fittings THEREFOR; Packaging ELEMENTS; Packages 5

B05B - Spraying APPARATUS; Atomising APPARATUS; Nozzles 4

Top 15 of 25 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Glaxo Group Limited's patent record in context - here's where to go next.

Glaxo Group Limited's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 69.2% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #2,929 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Glaxo Group Limited against Alcon Research, Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 43.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.